Logo

Prescient Medicine Holdings: Tony Grover

Nov 12, 2019

Tony Grover has been named the chief commercial officer of Prescient Medicine Holdings where he will build and execute go-to-market strategies. Grover was vice president of business development at Banyan Biomarkers. Prior to that, he held various positions at PhotoThera. His immediate focus at Prescient will be the LifeKit Predict test, an in vitro diagnostic test for identifying patients at risk of opioid addiction. The test received breakthrough device designation in February 2018. Another test, LifeKit Prevent, for the detection of precancerous polyps and early-stage carcinomas, received breakthrough device designation in August 2019. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.